http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Je-Ryoung Kim(김제룡) (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
Chang-Eun Jang(장창은),Je-Ryoung Kim(김제룡) 대한종양외과학회 2015 Korean Journal of Clinical Oncology Vol.11 No.2
Purpose: The aim of this study is to evaluate the prognostic factors of the group who received neoadjuvant chemotherapy with a taxane-anthracycline combination regimen. Methods: We retrospectively analyzed for locally advanced breast cancer patients who received neoadjuvant chemotherapy with adjuvant extension with taxane-anthracycline combination regimen. 101 patients received neoadjuvant chemotherapy with docetaxel and doxorubicin, 46 patients received with epirubicin and paclitaxel. After curative surgery, adjuvant chemotherapy with the same regimen was performed. The adjuvant chemotherapy regimen was adjusted when the response to neoadjuvant chemotherapy was in disease progression. Results: The disease free survival is 78% after 5 years and 71% after 10 years for good response group; the disease free survival is 23% in 5 years and 23% in 10 years for the no response group (P<0.001). The overall survival is 93% after 5 years and 90% after 10 years for the good response group; the overall survival is 47% after 5 years and 38% after 10 years for the no response group (P<0.001). 13 patients of 17 patients who to be appeared in complete response were triple negative for breast cancer. Conclusion: In order to predict an oncologic outcome from locally advanced breast cancer patients who are treated with neoadjuvant chemotherapy with taxane-anthracycline based regimen, we can use pathologic complete response, an early response to neoadjuvant chemotherapy.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
